Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease

NCT01389024 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease
Stroke

Interventions

DRUG: Hydroxyurea
DRUG: Placebo

Sponsor

Johns Hopkins University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]